Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of “Buy” by Brokerages

by · The Cerbat Gem

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) have been assigned an average recommendation of “Buy” from the eighteen brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $59.82.

Several equities analysts recently weighed in on the company. Stifel Nicolaus assumed coverage on Kymera Therapeutics in a research report on Tuesday, May 20th. They set a “buy” rating and a $55.00 target price on the stock. UBS Group lowered their price objective on Kymera Therapeutics from $72.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, May 13th. Citigroup began coverage on Kymera Therapeutics in a research report on Thursday, March 13th. They issued a “buy” rating and a $52.00 price objective on the stock. Bank of America upgraded Kymera Therapeutics from a “neutral” rating to a “buy” rating and set a $51.00 price objective on the stock in a research report on Monday, June 2nd. Finally, Guggenheim restated a “buy” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research report on Tuesday, June 3rd.

Get Our Latest Stock Analysis on KYMR

Kymera Therapeutics Stock Performance

NASDAQ KYMR opened at $45.87 on Friday. The company has a market capitalization of $2.99 billion, a PE ratio of -14.80 and a beta of 2.07. The business’s fifty day moving average is $35.05 and its 200 day moving average is $35.77. Kymera Therapeutics has a fifty-two week low of $19.45 and a fifty-two week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last released its earnings results on Friday, May 9th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.10. The company had revenue of $22.10 million for the quarter, compared to the consensus estimate of $11.38 million. Kymera Therapeutics had a negative return on equity of 30.11% and a negative net margin of 409.07%. Kymera Therapeutics’s quarterly revenue was up 114.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.69) earnings per share. On average, sell-side analysts forecast that Kymera Therapeutics will post -2.79 EPS for the current year.

Insider Activity

In other news, Director Jeffrey W. Albers sold 6,349 shares of the company’s stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total transaction of $311,101.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Nello Mainolfi sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total value of $1,470,000.00. Following the transaction, the chief executive officer now directly owns 660,482 shares in the company, valued at approximately $32,363,618. This represents a 4.34% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 48,349 shares of company stock valued at $2,334,301. 16.01% of the stock is currently owned by insiders.

Institutional Trading of Kymera Therapeutics

A number of large investors have recently modified their holdings of the company. Rhumbline Advisers boosted its holdings in shares of Kymera Therapeutics by 9.0% in the first quarter. Rhumbline Advisers now owns 69,928 shares of the company’s stock valued at $1,914,000 after purchasing an additional 5,771 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Kymera Therapeutics by 121.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock valued at $24,535,000 after purchasing an additional 491,737 shares during the period. Millennium Management LLC boosted its holdings in shares of Kymera Therapeutics by 340.4% in the first quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock valued at $13,972,000 after purchasing an additional 394,562 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Kymera Therapeutics by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock valued at $849,000 after purchasing an additional 1,833 shares during the period. Finally, Eventide Asset Management LLC boosted its holdings in shares of Kymera Therapeutics by 15.2% in the first quarter. Eventide Asset Management LLC now owns 525,138 shares of the company’s stock valued at $14,373,000 after purchasing an additional 69,410 shares during the period.

Kymera Therapeutics Company Profile

(Get Free Report

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

Recommended Stories